Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | IgA Vasculitis | Case Report

Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement

Authors: Agnieszka Przygocka, Gian Marco Berti, Anita Campus, Francesco Tondolo, Gisella Vischini, Benedetta Fabbrizio, Gaetano La Manna, Olga Baraldi

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

We observe the increasing use of tumor necrosis factor (TNF) inhibitors in patients affected by chronic inflammatory diseases. These drugs provide good control of symptoms, contributing to significant improvement in the quality of life in individuals with high disease burden. On the other hand, along with their wider use and longer follow-up periods the number of reports regarding their adverse effects is also increasing. The reported complications include drug-induced vasculitis with possible kidney involvement. In the literature we can distinguish more frequently described ANCA-associated vasculitis and more rarely occurring immunoglobulin A vasculitis. Although uncommon, such complications may present with potentially life-threatening vital organ dysfunction; therefore, adequate monitoring and effective therapy are necessary.

Case presentation

We report two cases of TNF inhibitor-induced vasculitis with severe acute worsening of renal function and significant proteinuria. The first patient was receiving golimumab therapy for ankylosing spondylitis and the second patient was treated with adalimumab for psoriasis and psoriatic arthritis. In the second case dialysis treatment was necessary and the patient presented recurrence of vasculitis after rechallenge with adalimumab. Both patients underwent renal biopsy which showed findings compatible with drug-induced IgA vasculitis and both were treated successfully with corticosteroids and rituximab.

Conclusions

To the best of our knowledge this is the first report of rituximab use in drug-induced IgA vasculitis with renal involvement. Combination of corticosteroids and rituximab can be an effective therapy in case of vasculitis with kidney failure and a preferable option for selected patients with drug-induced IgA vasculitis compared to cyclophosphamide. More studies are necessary to establish suitable short- and long-term treatment. Given the rarity of this disorder, case reports and case series can provide practical guidance until additional studies become available.
Literature
1.
go back to reference Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.PubMed Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.PubMed
2.
go back to reference Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic Diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13(8):873–9.PubMedCrossRef Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic Diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13(8):873–9.PubMedCrossRef
3.
go back to reference Rasmussen C, Tisseyre M, Garon-Czmil J, et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun Rev. 2021;20(1):102707.PubMedCrossRef Rasmussen C, Tisseyre M, Garon-Czmil J, et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun Rev. 2021;20(1):102707.PubMedCrossRef
4.
go back to reference Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.PubMedCrossRef Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.PubMedCrossRef
5.
go back to reference Heineke MH, Ballering AV, Jamin A. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev. 2017;16(12):1246–53.PubMedCrossRef Heineke MH, Ballering AV, Jamin A. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev. 2017;16(12):1246–53.PubMedCrossRef
6.
go back to reference Grau RG. Drug-Induced Vasculitis: New insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015;17(12):71.PubMedCrossRef Grau RG. Drug-Induced Vasculitis: New insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015;17(12):71.PubMedCrossRef
7.
8.
go back to reference D’Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255(3):409–18.PubMedCrossRef D’Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255(3):409–18.PubMedCrossRef
9.
go back to reference Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune Disease. J Allergy Clin Immunol. 2016;137(1):19–27.PubMedCrossRef Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune Disease. J Allergy Clin Immunol. 2016;137(1):19–27.PubMedCrossRef
10.
go back to reference Gutiérrez-González LA. Biological Therapy-Induced systemic vasculitis. Curr Rheumatol Rep. 2016;18(7):39.PubMedCrossRef Gutiérrez-González LA. Biological Therapy-Induced systemic vasculitis. Curr Rheumatol Rep. 2016;18(7):39.PubMedCrossRef
11.
go back to reference Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30(10):2287–91.PubMed Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30(10):2287–91.PubMed
12.
go back to reference Usui J, Salvatore SP, Yamagata K. Clinicopathologic spectrum of renal lesions following Anti-TNF- α inhibitor therapy: a single Center experience. Kidney360. 2023;4(3):363–73.PubMedPubMedCentralCrossRef Usui J, Salvatore SP, Yamagata K. Clinicopathologic spectrum of renal lesions following Anti-TNF- α inhibitor therapy: a single Center experience. Kidney360. 2023;4(3):363–73.PubMedPubMedCentralCrossRef
13.
go back to reference Ramos-Casals M, Brito-Zerón P, Soto MJ. Autoimmune Diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847–61.PubMedCrossRef Ramos-Casals M, Brito-Zerón P, Soto MJ. Autoimmune Diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847–61.PubMedCrossRef
14.
go back to reference Duffy TN, Genta M, Moll S. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006 (2 Suppl 41):S106. Duffy TN, Genta M, Moll S. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006 (2 Suppl 41):S106.
15.
go back to reference Sokumbi O, Wetter DA, Makol A. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45. Sokumbi O, Wetter DA, Makol A. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.
16.
go back to reference Rolle AS, Zimmermann B, Poon SH. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol. 2013;19(2):90–3.PubMedCrossRef Rolle AS, Zimmermann B, Poon SH. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol. 2013;19(2):90–3.PubMedCrossRef
17.
go back to reference Hokama A, Sonosaki T, Zamami R. Crohn Disease complicated by IgA vasculitis during therapy with Tumor necrosis factor-α inhibitor. Pol Arch Intern Med. 2019;129(4):283–4.PubMed Hokama A, Sonosaki T, Zamami R. Crohn Disease complicated by IgA vasculitis during therapy with Tumor necrosis factor-α inhibitor. Pol Arch Intern Med. 2019;129(4):283–4.PubMed
18.
go back to reference Fukuda M, Sawa N, Ikuma D, et al. Endothelial damage-dominant Nephritis related to IgA Vasculitis after 11 years’ use of Infliximab for Rheumatoid Arthritis. Intern Med. 2023;62(1):81–5.PubMedCrossRef Fukuda M, Sawa N, Ikuma D, et al. Endothelial damage-dominant Nephritis related to IgA Vasculitis after 11 years’ use of Infliximab for Rheumatoid Arthritis. Intern Med. 2023;62(1):81–5.PubMedCrossRef
19.
go back to reference Kidney Disease. Improving global outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular Diseases. Kidney Int. 2021;100(4S):1–S276. Kidney Disease. Improving global outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular Diseases. Kidney Int. 2021;100(4S):1–S276.
20.
go back to reference Yaseen K, Nevares A, Tamaki H. A spotlight on Drug-Induced Vasculitis. Curr Rheumatol Rep. 2022;24(11):323–36.PubMedCrossRef Yaseen K, Nevares A, Tamaki H. A spotlight on Drug-Induced Vasculitis. Curr Rheumatol Rep. 2022;24(11):323–36.PubMedCrossRef
21.
go back to reference Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400–6.PubMedCrossRef Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400–6.PubMedCrossRef
22.
go back to reference Simms R, Kipgen D, Dahill S. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51(3):e11–4.PubMedCrossRef Simms R, Kipgen D, Dahill S. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51(3):e11–4.PubMedCrossRef
23.
go back to reference Alkhunaizi AM, Dawamneh MF. ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha. Int J Rheum Dis. 2017;20(11):1843–7.PubMedCrossRef Alkhunaizi AM, Dawamneh MF. ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha. Int J Rheum Dis. 2017;20(11):1843–7.PubMedCrossRef
24.
go back to reference Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. Ren Fail. 2009;31(8):745–8.PubMedCrossRef Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. Ren Fail. 2009;31(8):745–8.PubMedCrossRef
25.
go back to reference Wong AH, Wong WK, Looi LM. Propylthiouracil-Induced Antineutrophil cytoplasmic antibodies-Associated Vasculitis with renal and lung involvement. Case Rep Nephrol Dial. 2022;12(2):105–11.PubMedPubMedCentralCrossRef Wong AH, Wong WK, Looi LM. Propylthiouracil-Induced Antineutrophil cytoplasmic antibodies-Associated Vasculitis with renal and lung involvement. Case Rep Nephrol Dial. 2022;12(2):105–11.PubMedPubMedCentralCrossRef
26.
go back to reference Saint Marcoux B, De Bandt M. CRI (Club Rhumatismes et inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73(6):710–3.PubMedCrossRef Saint Marcoux B, De Bandt M. CRI (Club Rhumatismes et inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73(6):710–3.PubMedCrossRef
27.
go back to reference Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.PubMed Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.PubMed
28.
go back to reference Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29(12):2571–6.PubMed Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29(12):2571–6.PubMed
29.
go back to reference Hsu AC, Folami AO, Bain J. Gonadal function in males treated with cyclophosphamide for Nephrotic Syndrome. Fertil Steril. 1979;31(2):173–7.PubMedCrossRef Hsu AC, Folami AO, Bain J. Gonadal function in males treated with cyclophosphamide for Nephrotic Syndrome. Fertil Steril. 1979;31(2):173–7.PubMedCrossRef
31.
go back to reference Jones R, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.PubMedCrossRef Jones R, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.PubMedCrossRef
32.
go back to reference van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064–9.PubMedCrossRef van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064–9.PubMedCrossRef
33.
go back to reference Florez H, Morlà R, Castellanos-Moreira R. Sustained response to Rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis. Semin Arthritis Rheum. 2018;47(4):e15–6.PubMedCrossRef Florez H, Morlà R, Castellanos-Moreira R. Sustained response to Rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis. Semin Arthritis Rheum. 2018;47(4):e15–6.PubMedCrossRef
34.
go back to reference Funada M, Nawata M, Nawata A. Rapidly Progressive glomerulonephritis after introduction of certolizumab pegol: a case report. Mod Rheumatol Case Rep. 2021;5(1):11–5.PubMedCrossRef Funada M, Nawata M, Nawata A. Rapidly Progressive glomerulonephritis after introduction of certolizumab pegol: a case report. Mod Rheumatol Case Rep. 2021;5(1):11–5.PubMedCrossRef
35.
36.
go back to reference Paley MA, Edrees F, Kudose S. Successful use of Rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis. Saudi J Kidney Dis Transpl 2019 Jan-Feb;30(1):226–30. Paley MA, Edrees F, Kudose S. Successful use of Rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis. Saudi J Kidney Dis Transpl 2019 Jan-Feb;30(1):226–30.
37.
go back to reference Pillebout E, Alberti C, Guillevin L, CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int. 2010;78(5):495–502.PubMedCrossRef Pillebout E, Alberti C, Guillevin L, CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int. 2010;78(5):495–502.PubMedCrossRef
38.
go back to reference Maritati F, Fenoglio R, Pillebout E, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol. 2018;70(1):109–14.PubMedCrossRef Maritati F, Fenoglio R, Pillebout E, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol. 2018;70(1):109–14.PubMedCrossRef
39.
go back to reference Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with Nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186–92.PubMedCrossRef Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with Nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186–92.PubMedCrossRef
40.
go back to reference Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71.PubMedPubMedCentralCrossRef Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71.PubMedPubMedCentralCrossRef
41.
go back to reference Pillebout E, Rocha F, Fardet L. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044–6.PubMedCrossRef Pillebout E, Rocha F, Fardet L. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044–6.PubMedCrossRef
42.
go back to reference Gandhi P, Khurana B, Munjal RS. Hydralazine-Induced Vasculitis Cureus. 2023;15(2):e35306.PubMed Gandhi P, Khurana B, Munjal RS. Hydralazine-Induced Vasculitis Cureus. 2023;15(2):e35306.PubMed
43.
go back to reference Zuckerman R, Patel M, Costanzo EJ, et al. Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA Vasculitis. J Bras Nefrol. 2018 Apr-Jun;40(2):193–7. Zuckerman R, Patel M, Costanzo EJ, et al. Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA Vasculitis. J Bras Nefrol. 2018 Apr-Jun;40(2):193–7.
46.
go back to reference He D, Wang R, Liang S, et al. Comparison of secondary IgA Nephropathy in patients with ankylosing spondylitis and rheumatoid arthritis. Mod Rheumatol. 2020;30(4):648–56.PubMedCrossRef He D, Wang R, Liang S, et al. Comparison of secondary IgA Nephropathy in patients with ankylosing spondylitis and rheumatoid arthritis. Mod Rheumatol. 2020;30(4):648–56.PubMedCrossRef
47.
go back to reference Strobel ES, Fritschka E. Renal Diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524–30.PubMedCrossRef Strobel ES, Fritschka E. Renal Diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524–30.PubMedCrossRef
48.
49.
go back to reference Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA Nephropathy. Clin Rheumatol. 2007;26(7):1132–3.PubMedCrossRef Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA Nephropathy. Clin Rheumatol. 2007;26(7):1132–3.PubMedCrossRef
50.
go back to reference Grewal SK, Wan J, Denburg MR, et al. The risk of IgA Nephropathy and glomerular Disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176(5):1366–9.PubMedPubMedCentralCrossRef Grewal SK, Wan J, Denburg MR, et al. The risk of IgA Nephropathy and glomerular Disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176(5):1366–9.PubMedPubMedCentralCrossRef
51.
go back to reference Singh NP, Prakash A, Kubba S, et al. Psoriatic Nephropathy–does an entity exist? Ren Fail. 2005;27(1):123–7.PubMed Singh NP, Prakash A, Kubba S, et al. Psoriatic Nephropathy–does an entity exist? Ren Fail. 2005;27(1):123–7.PubMed
52.
go back to reference Kamath S, Ahmed T, Rana F, et al. Rare case of ankylosing spondylitis complicated by IgA vasculitis. BMJ Case Rep. 2022;15(11):e252182.PubMedCrossRef Kamath S, Ahmed T, Rana F, et al. Rare case of ankylosing spondylitis complicated by IgA vasculitis. BMJ Case Rep. 2022;15(11):e252182.PubMedCrossRef
53.
go back to reference Nassif ND, Rosler DA, Joint Saga. Human Leukocyte Antigen (HLA) B27 ankylosing Spondylitis and Sacroiliitis Association with Henoch-Schönlein Purpura. Cureus. 2023;15(5):e39041.PubMedPubMedCentral Nassif ND, Rosler DA, Joint Saga. Human Leukocyte Antigen (HLA) B27 ankylosing Spondylitis and Sacroiliitis Association with Henoch-Schönlein Purpura. Cureus. 2023;15(5):e39041.PubMedPubMedCentral
54.
go back to reference Vaz AS, Penteado R, Cordinhã C, et al. IgA vasculitis (Henoch-Schönlein purpura) Nephritis and psoriasis in a child: is there a relationship? J Bras Nefrol. 2021;43(4):603–7. Vaz AS, Penteado R, Cordinhã C, et al. IgA vasculitis (Henoch-Schönlein purpura) Nephritis and psoriasis in a child: is there a relationship? J Bras Nefrol. 2021;43(4):603–7.
55.
go back to reference Farisogullari B, Cuceoglu MK, Oral H, et al. Biologics for immunoglobulin a vasculitis: targeting vasculitis or comorbid Disease? Intern Emerg Med. 2022;17(6):1599–608.PubMedCrossRef Farisogullari B, Cuceoglu MK, Oral H, et al. Biologics for immunoglobulin a vasculitis: targeting vasculitis or comorbid Disease? Intern Emerg Med. 2022;17(6):1599–608.PubMedCrossRef
56.
57.
go back to reference Chiu HY, Huang HL, Li CH, et al. Increased risk of glomerulonephritis and chronic Kidney Disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol. 2015;173(1):146–54.PubMedCrossRef Chiu HY, Huang HL, Li CH, et al. Increased risk of glomerulonephritis and chronic Kidney Disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol. 2015;173(1):146–54.PubMedCrossRef
Metadata
Title
Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement
Authors
Agnieszka Przygocka
Gian Marco Berti
Anita Campus
Francesco Tondolo
Gisella Vischini
Benedetta Fabbrizio
Gaetano La Manna
Olga Baraldi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03439-0

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.